Literature DB >> 8920922

A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo.

M Shimizu1, T Yoshimoto, S Nagata, A Matsuzawa.   

Abstract

We tried to induce tumor cell death in vivo through Fas (CD95)-mediated apoptosis. Murine hepatoma MH 134 (Fas-) was transfected with murine Fas antigen cDNA. Fas+ F6b but not Fas- N1d cells underwent apoptosis after treatment with anti-Fas antibody in vitro. The possibility of eradicating tumor cells in vivo with anti-Fas antibody was investigated using double-mutant gld/gld lpr/lpr mice which lack both Fas ligand (FasL) and Fas to avoid cytotoxic activity of the antibody to the liver and interference from endogenous FasL. A single administration of anti-Fas antibody efficiently suppressed the growth of F6b tumors but not that of N1d tumors in these mice. Thus, the therapy with Fas-FasL system may be a promising approach for cancer treatment, and this model is useful for study on in vivo apoptosis-mediated antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8920922     DOI: 10.1006/bbrc.1996.1669

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.

Authors:  Jaime F Modiano; Beth A Lindborg; Ron T McElmurry; Mitzi Lewellen; Colleen L Forster; Edward A Zamora; Jerome Schaack; Donald Bellgrau; Timothy D O'Brien; Jakub Tolar
Journal:  Cancer Immunol Immunother       Date:  2015-08-07       Impact factor: 6.968

Review 2.  Shared pathways: death receptors and cytotoxic drugs in cancer therapy.

Authors:  I Peták; J A Houghton
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 3.  Biochemical and molecular mechanisms regulating apoptosis.

Authors:  K S Saini; N I Walker
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.842

4.  Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer.

Authors:  Motomu Shimizu; Takayuki Yoshimoto; Akio Matsuzawa; Yasutaka Takeda
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

5.  Significant role of Fas ligand-binding but defective Fas receptor (CD95) in lymph node hyperplasia composed of abnormal double-negative T cells.

Authors:  Akio Matsuzawa; Motomu Shimizu; Yasutaka Takeda; Hisashi Nagase; Kazutoshi Sayama; Mikio Kimura
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.